J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Product Security Engineer

Full-TimeUpdated on 10/23/2026
$102k - $177.1k
Expert
Bachelor's
New Mexico, USA+49 moreMore locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | California, USA | Vermont, USA | Wyoming, USA | Connecticut, USA | Texas, USA | Montana, USA | Florida, USA | New Hampshire, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Hawaii, USA | Wisconsin, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | New Jersey, USA | Indiana, USA | Louisiana, USA | Alaska, USA | Michigan, USA | Illinois, USA | Alabama, USA | Danvers, MA, USA | Idaho, USA
HybridHybrid work; remote may be considered case-by-case with company approval. Travel up to 10%-20%.
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • At least 10 years of industry experience in information security.
  • At least 8 years of experience with embedded systems, Internet of Things, or medical device cybersecurity.
  • A bachelor's degree or equivalent.
  • Experience generating threat models without threat modeling tools.
  • Experience performing risk assessments using CVSS 3.1 or higher, with STRIDE per element.
  • Ability to write technical security requirements for embedded systems and web platforms based on current regulations.
  • Understanding and experience executing third-party penetration testing, vulnerability scanning, CVSS, and general security testing principles.
  • Experience supporting regulatory security submissions and ensuring compliance with FDA Cybersecurity Guidance (2025), EU MDR, NIST 800-53, IMDRF, and AAMI TIR57.
  • Knowledge of real-time operating systems hardening techniques and cloud security principles.
  • Ability to generate software bills of materials from software source code, binaries, firmware, and operating systems.
  • Ability to generate pre-market risk assessments against threat models using STRIDE and post-market risk assessments via software composition analysis software bill of materials scans.
  • Ability to generate medical-device security architecture views, potentially including Global System View, Multi-Patient Harm View, and Updateability/Patchability View, detailing system boundaries, data flows, and external interactions to show risk mitigation, ensure transparency, and support post-market management.
  • Ability to translate technical security requirements into solutions, provide secure-coding recommendations, and execute reviews.
  • Data privacy experience, including HIPAA and GDPR.
  • Understanding of industry standards and certifications such as HITRUST and ISO 27001.
  • Ability to work autonomously and proactively identify product security opportunities within Heart Recovery.
  • Ability to lead large projects and track project-plan timelines from a security perspective.
  • Ability to create and deliver cybersecurity awareness campaigns and other communications.
  • Ability to solve problems creatively and focus on internal and external customers.
  • Ability to communicate, collaborate, network, interface, and influence at all organizational levels across sectors and functions globally; strong leadership skills.
Responsibilities
  • Drive alignment with Johnson & Johnson Product Security’s overarching framework and support the Product Security strategy and objectives within Heart Recovery.
  • Define and implement secure boot, firmware integrity validation, and anti-tamper mechanisms to protect Heart Recovery device firmware against unauthorized modification.
  • Enforce cryptographic protocols for data at rest and in transit, ensuring compliance with FDA cybersecurity requirements, NIST 800-175, FIPS 140-3, and IEC 62443.
  • Define and implement key management infrastructure, including PKI, HSMs, TPMs, and secure enclave integration, for device identity, authentication, and software signing.
  • Develop real-time vulnerability assessment techniques for security flaws in Bluetooth LE, NFC, Wi-Fi, 5G, and proprietary RF communications used by Heart Recovery medical devices.
  • Implement Zero Trust security for device-to-cloud connectivity, integrating mTLS and continuous authentication models into clinical applications.
  • Oversee secure over-the-air update mechanisms, including firmware rollbacks, code signing, and supply-chain integrity validation.
  • Lead Secure Development Lifecycle practices by integrating threat modeling, static and dynamic analysis, fuzz testing, and formal verification into development.
  • Work with R&D Engineering to define hardware security architecture, including trust zones, hardware root of trust, and secure microcontroller protections.
  • Implement memory-safety strategies to mitigate buffer overflows, side-channel attacks, and execution vulnerabilities in real-time operating systems and bare-metal firmware.
  • Respond as needed to customer cybersecurity questionnaires and contractual language for post-market medical devices under the role’s responsibility.
  • Own product security processes for supported products throughout pre-market and post-market product development lifecycles; review product security requirements, recommend design solutions, complete quality documentation and threat modeling, coordinate third-party penetration testing, conduct software architecture reviews and design recommendations, code analysis, and other security testing.
  • Monitor marketed Heart Recovery devices for new vulnerabilities, assist with patching and remediation plans, and respond to customer security questionnaires and review security language in contractual agreements as needed.
Desired Qualifications
  • Experience leading or participating in formal security audits.
  • Experience with operating systems such as QNX QOS, Yocto, Linux Ubuntu, and Alpine.
  • Familiarity with FDA and other global regulatory cybersecurity guidance requirements and submission processes.
  • Experience with web applications and server hardening, including AWS or Azure, OWASP Top 10, and blue-team techniques.
  • Experience in cybersecurity pre-sales and software development.
  • CISSP, CISM, or another security certification.
  • A master's degree or other advanced degree.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.